A Decade of "Just As Good"
For the past decade, telerehabilitation research has ended with the same sentence: no significant difference compared to in-person rehabilitation. It appeared at the end of nearly every meta-analysis, so consistently that it began to feel like a template.
That sentence was useful. It reassured payers, convinced hospital administrators to launch pilots, and gave patients permission to try something new. But it also created a ceiling. Telerehab was, at best, "not worse." Nobody was willing to say it was better.
In clinical practice, this framing had a specific consequence. When an orthopedic surgeon is already running a busy practice with an established PT referral network, "not worse" is not a compelling reason to change anything. The cost of switching — new workflows, new technology, new patient education — needs to be justified by something stronger than equivalence.
That justification now exists.
What "Non-Inferior" Actually Meant
The non-inferiority data was solid but limited. A 2025 meta-analysis pooled 20 RCTs covering 3,706 total knee arthroplasty (TKA) patients[1]:
| Outcome | SMD | 95% CI | p-value | Interpretation |
|---|---|---|---|---|
| Pain | -0.15 | -0.47 to 0.16 | 0.34 | No significant difference |
| Physical function | -0.04 | -0.19 to 0.12 | 0.62 | No significant difference |
Confidence intervals crossing zero. Effect sizes approaching null. This is what non-inferiority looks like: telerehab does not harm patients, but there is no detectable benefit over conventional care. For a surgeon evaluating whether to adopt a new modality, this conclusion does not move the needle.
The Scale Tips: 25 RCTs, 4 Superior Outcomes
A meta-analysis published in December 2024 rewrites the narrative. It included 25 RCTs with 4,402 TKA patients — the largest pooled analysis of telerehabilitation after knee replacement to date[2].
The conclusion is no longer "no difference." Telerehabilitation was significantly superior to conventional rehabilitation on four outcomes:
| Outcome | Direction | Clinical Significance |
|---|---|---|
| Pain (VAS/NRS) | Telerehab < Conventional | Better post-operative pain control |
| Passive flexion ROM | Telerehab > Conventional | Faster range of motion recovery |
| Quadriceps strength | Telerehab > Conventional | Greater strength restoration |
| Healthcare cost | Telerehab < Conventional | Lower total cost of care |
The shift from "no difference" to "significantly superior" is not just a statistical upgrade. It fundamentally changes the clinical conversation.
Why the Conclusions Flipped
The evidence did not shift because telerehabilitation suddenly improved. It shifted because the studies got better.
Sample size. Earlier meta-analyses pooled RCTs with small samples (n=30-80), insufficient to detect moderate effect sizes. The new analysis incorporated 5 additional larger trials, pushing total enrollment from 3,706 to 4,402 and increasing statistical power to detect real differences.
Intervention quality. Early "telerehab" interventions were often little more than exercise videos emailed to patients. Recent RCTs use genuine digital platforms: real-time feedback, personalized progression, anomaly detection, and bidirectional communication with the clinical team. Higher fidelity interventions produce larger effect sizes.
Follow-up duration. The advantages of telerehabilitation take time to manifest. At 6 weeks post-surgery, both groups look similar. But at 3-6 months, when the telerehab group's adherence advantage compounds into a functional advantage, the gap appears. Newer RCTs with longer follow-up periods captured this delayed benefit.
In short, the intervention did not change. The measurement did.
The Evidence Is Converging
This is not an isolated finding. Multiple independent lines of evidence are pointing in the same direction.
Cognitive-motor dual-task training. A 2026 RCT tested telerehabilitation that combined cognitive training with motor exercises in older TKA patients[3]. The telerehab dual-task group showed superior outcomes in pain, dual-task performance, and sensorimotor function compared to conventional rehabilitation. This matters because the population that needs TKA the most — older adults — is also the population most likely to benefit from integrated cognitive-motor protocols.
AAOS 2026 real-world data. A study of 1,699 TKA patients presented at AAOS found that remote therapeutic monitoring (RTM) groups had lower costs with no worse clinical outcomes[4]. Critically, this study validated RTM in the geriatric population, directly addressing the common objection that digital rehab is only viable for younger, tech-savvy patients.
Structural adherence advantage. Digital rehabilitation platforms consistently report exercise adherence rates of 65-85%, compared to 40-60% for traditional home exercise programs. The difference is structural, not motivational: push notifications, real-time feedback, visual progress tracking, and connection to the care team make adherence the path of least resistance rather than an act of willpower.
Patient satisfaction. Among patients who have actually used telerehab (not hypothetical surveys), satisfaction ranges from 93.7% to 99%. Ninety-two percent found the technology easy to use. These numbers are well above typical health technology adoption benchmarks.
What This Changes for Clinical Decision-Making
For the practicing orthopedic surgeon, these data change the framing of the conversation.
The old question was: does telerehab work? That question has been answered definitively.
The new question is: why aren't we offering it?
The regulatory and reimbursement environment is catching up. CMS remote therapeutic monitoring codes now provide a clear payment pathway: CPT 98985 ($51/month) and 98979 ($26/month) for device supply and interactive communication, respectively[5]. The CMS TEAM model — mandatory for 741 hospitals — creates a forcing function by holding hospitals financially accountable for post-discharge outcomes. Hospitals that cannot track post-surgical rehabilitation performance will absorb the risk.
The economics follow the evidence. When telerehab was "just as good," the value proposition was cost savings alone — a necessary but often insufficient argument for adoption. Now that telerehab is demonstrably better on clinical outcomes, the case compounds: better outcomes, lower costs, higher adherence, and a reimbursement pathway that rewards rather than penalizes adoption.
The surgeon who does not offer telerehabilitation is no longer making a neutral choice. They are choosing the inferior option.
From Evidence to Implementation
The evidence has shifted. But evidence alone does not change clinical practice — implementation does.
We wrote in our previous article about the 83% of patients who prefer hybrid rehabilitation — a combination of in-person clinical touchpoints and daily digital monitoring at home. At that time, the case rested primarily on patient preference and non-inferiority data. The new evidence adds a second pillar: not just "patients want it" but "the data shows it's better."
The question is no longer whether telerehabilitation works. The question is when your patients will start using it.
References
-
Telerehabilitation for Total Knee Arthroplasty: A Systematic Review and Meta-analysis. JMIR. 2025. JMIR
-
Telerehabilitation versus conventional rehabilitation after total knee arthroplasty: a systematic review and meta-analysis of 25 randomized controlled trials. 2024. PubMed
-
Dual-task telerehabilitation in older adults after total knee arthroplasty: a randomized controlled trial. 2026. PubMed
-
Remote Therapeutic Monitoring After TKA May Be Safe, Cost-Effective. Healio Orthopedics. 2026. Healio
-
2026 CMS Final Rule: RTM Codes and Reimbursement. Limber Health. 2026. Limber Health